Latest News
IBA and Shreeji sign agreement to deploy four cyclotrons for PET radiopharmaceuticals in India
19 February 2026 - Particle accelerator technology company Ion Beam Applications S.A. (IBA) (Euronext Brussels:IBAB) on Thursday announced a new agreement with Shreeji Imaging and Diagnostic Centre Pvt Ltd, an Indian manufacturer and distributor of f...
AVEO Oncology completes first interim analysis in global Phase 3 FIERCE-HN study
19 February 2026 - US-based AVEO Oncology, an LG Chem (KRX:051910) company, announced on Wednesday that the 20mg/kg dose of ficlatuzumab has been chosen for the combination arm of the Phase 3 registrational FIERCE-HN clinical trial following the plan...
Cedar Health Research opens new embedded research site within Texas Native Health
19 February 2026 - Cedar Health Research, a Texas-based clinical trial network focused on underserved patients, and Texas Native Health, a Dallas nonprofit serving American Indian and Alaska Native communities, announced on Wednesday that they have o...
Hansa's imlifidase Biologics License Application accepted by FDA
19 February 2026 - Swedish biopharmaceutical company Hansa Biopharma AB (STO:HNSA) announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for imlifidase.The FDA's filing review ...
Novartis reports positive Phase III results for remibrutinib in chronic inducible urticaria
...